18 November 2026
The agency issued the alert with
the European Centre for Disease Prevention and Control
(ECDC) after analysing progress on targets to reduce
infections caused by resistant bacteria – often described
as “superbugs” – that thrive in healthcare
settings.
Instead of achieving the target of a five
per cent fall in infections from the common hospital
bacterium Klebsiella pneumoniae, they rose by an
estimated 72 per cent between 2019 and 2025.
And
infections with E. coli bacterium – which are also
resistant to regular antibiotics known as cephalosporins –
were set a target of a 10 per cent decrease. Instead, they
rose by more than 16 per cent.
System bugs
WHO said that it found
resistance to key antibiotics in at least half of the
samples of Klebsiella pneumoniae and another common
bug, Acinetobacter, in about one in two countries in
Europe.
Dr Marc-Alain Widdowson, head of health
security at WHO/Europe said that in many countries in the
region, “the antibiotics doctors usually reach for first
are failing against serious hospital infections”. When
these treatments fail to work, doctors turn to stronger
drugs normally kept for the most serious cases that are
called carbapenems.
“When those stop working too,
what’s left is mostly a small group of last-resort drugs
that are often expensive and not available in every
country,” he explained. “Each time one of these lines of
defence falls, patients move closer to having no good
options at all. That matters, because people whose first
antibiotic doesn’t work against their infection are more
likely to die in hospital.”
Advertisement – scroll to continue reading
WHO noted that of 51
countries analysed, 16 still lack a standardized national
approach and national coordination, hampering the effort to
overcome antimicrobial resistance globally.
In the
dark
And in hospitals where few blood samples are
taken to identify the bacteria behind an infection, doctors
often “have to choose an antibiotic without knowing which
will work”, the agency said.
For patients, this
raises the risk of starting treatment on a drug that will
not work. And for health systems, “it means planning
half-blind”, WHO stressed, since without reliable data,
countries cannot tell where resistance is spreading or
whether their efforts to stop it are working. “Better
testing would help on both fronts, giving patients the right
drug sooner and countries a clearer view of the
threat.”
In more positive news, the estimated rate
of bloodstream infections caused by resistant
Acinetobacter has almost halved since the high levels
seen in 2021 during the COVID-19
pandemic.

